PISA, ITALY

The CNR Institute of Clinical Physiology is a Center for basic, clinical, technological and epidemiological research. This multidisciplinary translational approach has been the key strategy of driving collaborations through the years on a flexible and problem-solving basis.

The main interest of the Institute is in the field of cardiovascular diseases, which are dealt with through a multiorgan and multisystem prospective, covering associated pathologies of the lungs, kidneys, and the neuro-endocrine and metabolic systems. Research is mainly developed in the area of physiopathology and methodology, in which multidisciplinary projects merge in the fields of experimental and clinical medicine, in line with the tradition of the Institute. CNR has carried out several pharmacological and medical trials in the cardiovascular disease field, developing during its activity a wide clinical database for selection of study populations, characterized in terms of genetics/biohumoral data as well as of clinical imaging repository (Echo, MRI, CT, Angiography).

The department of non-invasive cardiac imaging performs state of the art cardiac imaging for clinical care of patients and research projects. We participated in the EVINCI study as a CT coronary angiography core lab.

FOUNDATION FOR RESEARCH AND TECHNOLOGY HELLAS – FORTH

IOANNINA, GREECE

The Foundation for Research and Technology - Hellas (FORTH), established in 1983, is one of the largest research centers in Greece with well - organized facilities and highly qualified personnel.

Over the years, FORTH has become one of the top European research centers, thanks to its high impact research results and its valuable socioeconomic contribution. FORTH/IMBB (www.imbb.forth.gr): The Institute of Molecular Biology and Biotechnology (IMBB) is based in Heraklion (Crete), and is conducting basic and applied research in established and emerging areas of Biomedical science. IMBB was founded in 1983 and is part of the Foundation of Research and Technology-Hellas (FORTH), one of the largest research centers in Greece. FORTH/IMBB-BR www.imbb.forth.gr & www.bri.forth.gr): IMBB-BR was founded in 1998 under the auspices of the Greek General Secretariat of Research and Technology (GSRT) as an independent Institute. The work in the project will be mainly undertaken by the Unit of Medical Technology & Intelligent Information Systems (MedLab). MedLab is a highly innovative and self-contained research unit strongly activated in the fields of Biomedical Engineering and development of Intelligent Information systems. It has an internationally acknowledged excellence in conducting high quality scientific research and developing innovative Information Technology (IT) applications, products and services. Most of the Unit activities are based on international collaborations in the framework of European and Nationally funded projects (FP5, FP6, FP7, Horizon 2020). MedLab’s research activities cover a variety of subjects and they are classified into the following domains: Biomedical Research, Automated Diagnosis - Processing and analysis of biomedical signals (e.g. ECG, EMG) and images (e.g. MRI, ultrasound), Biomagnetism and Biomaterials, Bioinformatics, Networks, Medical Informatics, Data mining, Applications of predictive data mining methodologies, especially in clinical domain. MedLab has previous experience in the analysis of cardiovascular data, towards the development of decision support systems, both for the diagnosis but also for the prognosis of CVD (prediction of increase in stenosis as well as prediction of events).

FACULTET INZENJERSKIH NAUKA UNIVERZITETA U KRAGUJEVCU – FINK

KRAGUJEVAC, SERBIA

Faculty of Engineering, University of Kragujevac Faculty of Engineering achieves significant results in the field of bioengineering which are prominent at the national and international level.

The Centre for Bioengineering at Faculty of Engineering is carrying a number of international scientific projects in the field of modeling, software development and data mining. The Centre for Bioengineering is headed by Prof. Dr. Nenad Filipovic, who has a rich experience in computer simulation of the cardiovascular system. He is developing a computer model for plaque formation and development under the FP7 project ARTreat (www.artreat.org and www.artreat.kg.ac.rs). Centre for Bioengineering is conducting an important project with Harvard University in the field of modeling in physiology. Also the group is involved in a project with University of Texas on the modeling of blood microcirculation, margination and endocytosis of particles. Previously, researchers of the Centre participated in a number of international projects, mainly with the task of biomedical engineering modeling; collaboration included various institutions, as University of Vienna, University of Tubingen, PolyU University in Hong Kong, University of Munich, University of Heidelberg, related to patient specific cardiovascular atherosclerotic disease modeling. A large number of scientific publications have been issued as the result of these efforts, spanning from blood flow modeling, cartilage muscle and tissue mechanics, thrombosis and plaque growth modeling, to molecular diffusion and multiscale modeling. The Center is capable, with its hardware, software and researchers, to participate in activities within the project.

ALACRIS THERANOSTICS GMBH – ALACRIS

BERLIN, GERMANY

Founded in 2008, Alacris Theranostics GmbH is a SME focusing on developing new approaches for personalised medicine, including Next Generation Sequencing (NGS) based treatment guidance, clinical trial stratification, biomarker discovery and advanced bioinformatics.

Founded in 2008, Alacris Theranostics GmbH (www.alacris.de) is a SME focusing on developing new approaches for personalised medicine, including Next Generation Sequencing (NGS) based treatment guidance, clinical trial stratification, biomarker discovery and advanced bioinformatics. Alacris holds an exclusive worldwide commercial license for the systems biology modelling system ModCellTM, a technology developed with the Max Planck Institute for Molecular Genetics, Berlin (MPI-MG). Alacris is currently involved in a number of major research projects, contributing a range of technologies and expertise, including database creation and management, high-throughput sequencing and development of the ModCellTM software for virtual patient modelling.

TURUN YLIOPISTO – UTU

TURKU, FINLAND

University of Turku, Turku PET Centre Turku PET Centre at University of Turku is the Finnish national research institute that uses short-lived positron emitting isotopes in the field of medical research.Currently, the centre employs more nearly 200 staff members and investigators from various research fields.

Exprivia Healthcare IT S.r.l. – EHIT

TRENTO, ITALY

Listed on the Italian Stock Exchange since 2000 and in the STAR MTA segment since October 2007, Exprivia has a team of more than 2000 individuals, located in its headquarters in Molfetta (Bari) and throughout its offices in Italy (Trento, Vicenza, Milan, Padua, Turin, Piacenza, Genoa, Rome and Palermo) and abroad (Spain, USA, Mexico, Guatemala, Peru, Brazil and China).

Exprivia Healthcare IT (Exprivia) is the Exprivia Group subsidiary dedicated to the Healthcare IT Market. With a team of 350 professionals along with thirty years of experience in the healthcare sector focused on the design and development of innovative solutions, Exprivia is one of the first five players in the Italian Healthcare IT market.

Exprivia Healthcare IT provides all services required for the provision and conduction of its applications, including licensing, installation, configuration, training and startup. Maintenance services include helpdesk, remote and on site support, as well as 24x365 technical support.

More than 500 Italian public and private hospitals and healthcare centres use solutions by Exprivia to provide services to approximately 20 million patients. The Exprivia solutions are also used by over 40 hospitals in US, Mexico and Latin America.

UNIVERSITAET ZUERICH – UZH

ZURICH, SWIZZERLAND

The University Hospital Zurich is the largest University Hospital in Switzerland. The Chair of the Department of Nuclear Medicine is also the director of Cardiac Imaging which has a longstanding history of innovation in cardiac imaging.

The Department of Nuclear Medicine has several double board certified physicians with certificates in Nuclear Medicine and Radiology as well as Nuclear Medicine and Cardiology. We are also taking care of gender balance considering that two of our six attending physicians are female and four of our nine residents are female. In the field of cardiac imaging we scientifically deal mainly with new developments in the field of cardiac CT imaging and perfusion scanning with several Isotopes such as ammonia and water as well as MR. Through our longstanding active work in the field we have several collaborations with other national and international centers. The current research activities in Cardiac Imaging are focused on improvement of integrating cardiac imaging. The most up-to-date image acquisition algorithms are rapidly tested and implemented in our center, e.g. we were one of the first centers worldwide to implement and routinely perform cardiac CT with prospective ECG-triggering. The University Hospital Zurich has actively participated as research partner, recruiting center, and core lab for hybrid imaging in the original FP7-funded EVINCI project.

Research activity embraces different fields of cardiovascular diseases with special focus on coronary artery disease, heart failure, and cardiovascular imaging. The mission of FTGM is the reinforce of the relationships between Regional Health System and research organizations in Tuscany (Universities and the National Research Council-CNR), in Italy and in Europe.

MICRONIT MICROFLUIDICS B.V. – MICRONIT

ENSCHEDE, NETHERLANDS

Micronit was founded in 1999 and currently employs around 100 enthusiastic and dedicated people.

Micronit focuses on the total development process of microfluidic devices, from design to high-volume manufacturing. The products are manufactured in their high-tech cleanroom facilities located in Enschede, the Netherlands and Dortmund, Germany. Micronit has extensive know-how and intellectual property in the field of micromachining for microfluidic applications. The company is leading in the field of microfluidics and has close ties to both industry and academia. The people involved in the SMARTool project have an extensive track record on a wide range of projects both on commercial basis as well as cooperative projects funded by the European Union or funded on a national or regional level. Several of these projects revolve around cell or tissue culturing platforms or cell-based biosensors.

Biotronics3D Ltd. – B3D

LONDON, UNITED KINGDOM

Biotronics3D, was established in 2004 in London and opened an R&D centre in Cambridge in 2009. The company develops and commercialises cloud based medical image analysis and visualisation tools.

By applying a novel and innovative technology and business model to an old market, the company achieved fast market growth in the UK and Europe. The main product, 3DNet (www.3dnetmedical.com) has received FDA 510K market clearance and CE mark, while it is being used by around 12,000 users worldwide managing a few petabytes of medical imaging data, across a cluster of datacentres. The company enjoys a number of research collaborations with the UK academia such as ICR, UCL, University of Nottingham and City University.